Haemoglobinopathies congenital Recruiting Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Haemoglobinopathies / Haemoglobinopathy / Hemoglobinopathy / Hemoglobinopathies / Haemoglobinopathy NOS / Abnormal hemoglobin NOS

IndicationStatusPhase
DBCOND0026458 (Haemoglobinopathies congenital)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01050855Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant DisordersTreatment